Seminar SeriesSnakeholders and Stakeholders: How Zookeepers and Border Smugglers Set the Stage for Antivenom Commercialization in the USA
Seminar SeriesTransforming Patient Access to High-Cost, One-Time Treatments through Financial Engineering Innovation
Seminar SeriesFast Track to Final Drug Product: Understanding Costs, Challenges, and Timelines in Personalized Medicine Manufacturing
Seminar SeriesPRAX-222 Therapy for a Child: Prenatal Onset SCN2A Developmental and Epileptic Encephalopathy in a Named Patient Setting
Seminar Series"Control of starting material quality for oligonucleotide therapeutics" and "To Synthesis and Beyond…Production of oligos for ‘N-of-1’ therapies"
Seminar SeriesConnecting, Collaborating, Communicating, Challenges: Sharing experiences navigating family conversations in an n-of-1 investigational treatment setting
Seminar SeriesPatient Partners: Harnessing synergies to pursue ASOs as part of the AHC research portfolio
Seminar SeriesPotential Treatment: CMT2S Caused By IGHMBP2 Cryptic Splice Site Variant With ASO Based Therapeutic
Seminar SeriesSelecting the right candidate: Which disease-causing variants are eligible for N=1 ASOs?
Seminar SeriesFrom Mutation to Dose-able CRISPR Medicine In 3 Months: Obstacles & Actionable Paths Forward
